Kite Pharma Appoints Jian Irish, PhD as Senior Vice President of Supply Chain
December 01 2016 - 8:30AM
Business Wire
- Company Strengthens Supply Chain
Operations as it Prepares for Potential Approval and Launch of
KTE-C19 for Aggressive non-Hodgkin Lymphoma by the U.S. Food and
Drug Administration in 2017
Kite Pharma, Inc. (Nasdaq: KITE) today announced the appointment
of Jian Irish, Ph.D. as the company’s Senior Vice President of
Supply Chain. The appointment of Dr. Irish, who will be responsible
for establishing and securing a reliable supply chain, including
sourcing, logistics, inventory management, procurement, supply and
operations planning process, further increases the depth of an
industry-leading cell therapy Supply Chain organization.
“Jian brings a wealth of supply chain and product development
experience to Kite, as well as extensive international business
acumen,” said Tim Moore, Executive Vice President, Technical
Operations of Kite. “Her willingness to embrace new opportunities
to innovate, coupled with her ability to partner and cultivate
talent, makes Jian a great addition to the Technical Operations
senior leadership team.”
Dr. Irish will work closely with both the commercial and
technical operations organization to create operational strategies
for supply chain design, product life cycle management, launch and
commercialization as the company prepares for the potential
approval of Kite’s lead product candidate, KTE-C19, by the U.S.
Food and Drug Administration.
“Coming from a family of medical doctors, I learned from a very
young age to appreciate the power that medicine has to change
lives,” said Dr. Irish. “I am excited to be a part of Kite, a
company that is increasingly recognized for its leadership in CAR-T
therapy as well as its drive to find a cure for cancer. I look
forward to partnering with a stellar team of experienced
professionals who have a common commitment to excellence at every
level.”
Dr. Irish established her career in the biopharmaceutical
industry through various global leadership roles. She joins Kite
from Sanofi, where she most recently served as the Vice President
of Biologics Strategic Supply, Sourcing and Partnerships. She
also served as Vice President of Biologics Product Development
Technology Transfer at Sanofi. In these roles, Dr. Irish
oversaw the strategy and execution of the Biologics supply chain
and technical transfer processes to scale up Sanofi Biological
operations. Prior to Sanofi, Dr. Irish was the Executive
Director, General Manager of Japan Asia Pacific Supply Chain at
Amgen as well as the Executive Director, Global Head of Contract
Manufacturing where Dr. Irish made a critical impact in the
commercialization of Vectibix®, Xgeva®, and Enbrel®.
Dr. Irish holds a Bachelor of Science in Chemical Engineering
from East China University of Science and Technology in Shanghai,
China, a Master of Science and Ph.D. in Pharmaceutical Sciences
from Chiba University in Chiba, Japan, and a Master of Business
Administration from the Anderson School of Management at University
of California, Los Angeles.
About KTE-C19
Kite Pharma's lead product candidate, KTE-C19, is an
investigational therapy in which a patient's T cells are engineered
to express a chimeric antigen receptor (CAR) to target the antigen
CD19, a protein expressed on the cell surface of B-cell lymphomas
and leukemias, and redirect the T cells to kill cancer cells.
KTE-C19 has been granted Breakthrough Therapy Designation status
for diffuse large B-cell lymphoma (DLBCL), transformed follicular
lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) by
the U.S. Food and Drug Administration (FDA) and Priority
Medicines (PRIME) regulatory support for DLBCL in the EU.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company
engaged in the development of novel cancer immunotherapy products,
with a primary focus on engineered autologous cell therapy (eACT™)
designed to restore the immune system's ability to recognize and
eradicate tumors. Kite is based in Santa Monica, CA. For
more information on Kite Pharma, please
visit www.kitepharma.com. Sign up to follow @KitePharma on
Twitter at www.twitter.com/kitepharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The press release may, in some
cases, use terms such as "predicts," "believes," "potential,"
"proposed," "continue," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "will," "should" or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking
statements include statements regarding intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: the ability and timing of filing a biologics
license application with the FDA, obtaining regulatory approval
based on the studies of KTE-C19, commercially launching KTE-C19,
and the ability to establish and secure a reliable supply chain for
KTE-C19. Various factors may cause differences between Kite's
expectations and actual results as discussed in greater detail in
Kite's filings with the Securities and Exchange Commission,
including without limitation in its Form 10-Q for the quarter ended
September 30, 2016. Any forward-looking statements that are made in
this press release speak only as of the date of this press release.
Kite assumes no obligation to update the forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161201005388/en/
Kite PharmaChristine CassianoSVP, Corporate Communications &
Investor Relationsccassiano@kitepharma.comorGreg MannVP, Investor
Relationsgmann@kitepharma.com
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Aug 2024 to Sep 2024
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Sep 2023 to Sep 2024